WuXi Biologics News and Resources

WuXi Biologics has completed its first commercial Process Performance Qualification (PPQ) campaign for three 5,000L single-use bioreactors (SUBs) at its MFG20 facility in Hangzhou, marking a milestone in large-scale biologics manufacturing in Asia. This development makes the MFG20 site the first

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has introduced EffiX, a proprietary E. coli expression system engineered to enhance the production of recombinant proteins and plasmid DNA. The platform is designed to deliver high yields, exceptional

WuXi Biologics has successfully completed the Good Manufacturing Practice (GMP) inspection conducted by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities, MFG2 and MFG5, in Wuxi, China. The inspection concluded without issues, reinforcing the company’s adherence

WuXi Biologics has been awarded the Platinum Medal by the EcoVadis Sustainability Rating, marking its second consecutive year receiving the highest level of recognition. The rating evaluates companies on sustainability criteria, including Environment, Labour & Human Rights, Ethics, and Sustainable Procurement.

WuXi Biologics (“WuXi Bio”), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a partnership with Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. Under the agreement, Candid Therapeutics will acquire exclusive

WuXi Biologics, through its subsidiary WuXi Vaccines, has agreed to sell its manufacturing facility in Dundalk, Ireland, to Merck for $500 million. The deal is expected to close in the first half of the year, according to a company press

WuXi Biologics has announced a new service agreement with Sino Biopharm to discover a first-in-class monoclonal antibody (mAb) against an undisclosed target. The collaboration, unveiled on December 30, 2024, marks a key milestone in Sino Biopharm’s internationalization strategy and underscores

Aadi Bioscience, Inc. has entered into a significant licensing agreement with WuXi Biologics and HANGZHOU DAC Biotechnology Co., Ltd., aimed at developing and commercialising a portfolio of next-generation antibody-drug conjugates (ADCs). This collaboration gives Aadi exclusive rights to three preclinical

WuXi Biologics has announced significant accomplishments at its state-of-the-art greenfield site in Dundalk, Ireland, marking a key milestone in its global biomanufacturing network. The facility has completed multiple successful 16,000-liter Process Performance Qualification (PPQ) runs, with two completed runs achieving

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced plans to enhance its drug product (DP) capabilities at its Leverkusen, Germany facility. The company will add a new sterile filling line for prefilled syringes (PFS) using